WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (Nasdaq: ALTH) today reported results for its fiscal year ended December 31, 2008 and outlined its key objectives for 2009. For the year ended December 31, 2008, the Company reported a net loss of $51.7 million, or $0.69 per share, compared to a net loss of $39.4 million, or $0.60 per share, for 2007. Net cash used in operating activities during 2008 was $42.9 million. Cash, cash equivalents and investments in marketable securities as of December 31, 2008 totaled $84.0 million.
